TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02336607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine tablet (Plendil) alone
Description: Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine tablet (Plendil)+Hydrochlorothiazide
Description: Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)
Description: Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine tablets (Plendil)+Lisinopril (Zestril)
Description: Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
Study: NCT01180335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 4 cycles FEC followed by 4 cycles docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genomic driven chemotherapy
Description: High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
Study: NCT04139226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-11050
Description: CC-11050
Study: NCT02643459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: suPAR measurement
Description: The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.
Study: NCT01167803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Patients undergo anesthesia using remifentanil associated with desflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Patients undergo anesthesia using remifentanil associated with xenon
Study: NCT00721396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine
Study: NCT00371592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: 800 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyclovir placebo
Description: 800 mg placebo tablet taken orally twice daily
Study: NCT03746626

Intervention type: BEHAVIORAL
Intervention: Chaplain visit
Description: The patients will all see a chaplain routinely during 8-week stay according to their personal preference. The chaplain records the 'depth' and frequency of these encounters.

Intervention type: BEHAVIORAL
Intervention: Chaplain visit
Description: The patients will all see a chaplain routinely during 8-week stay according to their personal preference. The chaplain records the 'depth' and frequency of these encounters.

Intervention type: BEHAVIORAL
Intervention: Chaplain visit
Description: The patients will all see a chaplain routinely during 8-week stay according to their personal preference. The chaplain records the 'depth' and frequency of these encounters.
Study: NCT01809821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Sleep Education
Study: NCT00757237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam for Inhalation Solution (AZLI)
Description: Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalation Solution (TIS)
Description: Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
Study: NCT03067428

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as glucose powder three times daily during the meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fructose
Description: Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as fructose powder three times daily during the meal.
Study: NCT01335139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Description: Participants randomized to receive sublingual allergen tablet immunotherapy with placebo injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Description: Participants randomized to receive subcutaneous injection immunotherapy with placebo tablets. Subcutaneous immunotherapy was included as a positive control.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to double-placebo tablets and injections. This group was included as a negative control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants randomized to double-placebo tablets and injections. This group was included as a negative control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
Study: NCT01645072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Description: Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI \>55) will be eliminated from the diet and only food items with low glycemic index (GI \<55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The ongoing anti epileptic drug treatment will be continued without change.
Study: NCT02414308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose tissue stem cell injection
Description: Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
Study: NCT01933308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous high intensity training-CT80
Description: Continuous exercise training at 80% of peak work rate Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training at ventilatory threshold-CTVT
Description: Continuous exercise training at the ventilatory threshold Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval training-IT
Description: High intensity interval training Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
Study: NCT05398237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar Simulated Light (SSL)
Description: Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
Study: NCT02091817

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: Intervention will be examined on control group, and on experimental group as well.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intervention will be examined on control group, and on experimental group as well.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo will be given to control group and experimental group as well.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to control group and experimental group as well.
Study: NCT00876616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus+Mycophenolate mofetil
Description: FK506 4mg/d,MMF 1.0g/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: CTX 0.75g/m2 BSA
Study: NCT01521130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
Study: NCT01650558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care prophylaxis
Description: Daily trimethoprim sulfamethoxazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) prophylaxis
Description: Discontinue standard of care and start weekly CQ.
Study: NCT01557426

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound
Description: A linear ultrasound transducer will be used with ultrasound gel to obtain an image of subcutaneous structures and tissues over the involved body site. Ultrasound video will be recorded whenever possible, however studies that are not recorded will still be included. Video recording will be initiated once the desired image is obtained. Appropriate measurements will be made and views identified using the features of the ultrasound machine. Scanning of the contralateral body segment will then be performed. The ultrasound probe will be thoroughly cleaned and disinfected between ultrasound scans.
Study: NCT02572323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tesamorelin
Description: Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
Study: NCT02938026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Intensive Lifestyle Counselling
Study: NCT01959997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Redo PVI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI + RDN
Study: NCT02468180

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon-occluded retrograde transvenous obliteration
Description: Balloon-occluded retrograde transvenous obliteration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cyanoacrylate injection
Description: Endoscopic cyanoacrylate injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-butyl-2-cyanoacrylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lauromacrogol
Study: NCT01160289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2452473
Description: Administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2452473
Description: Administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2452473
Description: Administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: Administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: Administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: Administered orally, once daily for 12 weeks
Study: NCT02572323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tesamorelin
Description: Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
Study: NCT01160289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: Administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (tadalafil)
Description: Administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (tadalafil)
Description: Administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (tadalafil)
Description: Administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (tadalafil)
Description: Administered orally, once daily for 12 weeks
Study: NCT03395483

Intervention type: OTHER
Intervention: Haemodynamic monitoring
Description: see Group description
Study: NCT01096836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: macronutrient and energy manipulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: macronutrient and energy manipulation
Study: NCT02828735

Intervention type: DEVICE
Group type: OTHER
Intervention: respiration assessment
Description: Respiration Breathing Exercise
Study: NCT04506541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Care
Description: Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room.
Study: NCT03827135

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyriax manipulation
Description: Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle strechings.~Traction with rotation was not given in cases of bilateral arm pain. cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins.
Study: NCT03982641

Intervention type: PROCEDURE
Intervention: all colorectal cancer surgical procedures
Description: colorectal cancer surgical procedures

Intervention type: PROCEDURE
Intervention: all colorectal cancer surgical procedures
Description: colorectal cancer surgical procedures
Study: NCT00115505

Intervention type: OTHER
Intervention: quality-of-life assessment
Description: Complete Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form, EORTC QLQ-C30 and EORTC QLQ-BR23

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete the Employment and Informal Care Cost Assessment and Peripheral Neuropathy Assessments
Study: NCT01944007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cross-Linked Polyelectrolyte (CLP)
Description: CLP was administered orally, in capsules, for 9 consecutive days.
Study: NCT01160289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (tadalafil)
Description: Administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (LY2452473)
Description: Administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (LY2452473)
Description: Administered orally, once daily for 12 weeks
Study: NCT01001338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA594
Description: Uricosuric agent for the treatment of gout.
Study: NCT01944007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cross-Linked Polyelectrolyte (CLP)
Description: CLP was administered orally, in capsules, for 9 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cross-Linked Polyelectrolyte (CLP)
Description: CLP was administered orally, in capsules, for 9 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cross-Linked Polyelectrolyte (CLP)
Description: CLP was administered orally, in capsules, for 9 consecutive days.
Study: NCT02111447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol infusion with nasal oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol infusion with nasal oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol infusion with an LMA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane with an LMA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane with an LMA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane with an LMA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Isoflurane with an LMA
Study: NCT01054105

Intervention type: DRUG
Intervention: Iloprost
Description: Iloprost inhalation, 2.5 - 5mcg, 6 times per day

Intervention type: DRUG
Intervention: Iloprost
Description: Iloprost inhalation, 2.5 - 5mcg, 6 times per day